BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25269750)

  • 1. Estrogen receptor, progesterone receptor, interleukin-6 and interleukin-8 are variable in breast cancer and benign stem/progenitor cell populations.
    Schillace RV; Skinner AM; Pommier RF; O'Neill S; Muller PJ; Naik AM; Hansen JE; Pommier SJ
    BMC Cancer; 2014 Sep; 14():733. PubMed ID: 25269750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
    Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
    J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERα-36 regulates progesterone receptor activity in breast cancer.
    Konan HP; Kassem L; Omarjee S; Surmieliova-Garnès A; Jacquemetton J; Cascales E; Rezza A; Trédan O; Treilleux I; Poulard C; Le Romancer M
    Breast Cancer Res; 2020 May; 22(1):50. PubMed ID: 32429997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR.
    Green AR; Young P; Krivinskas S; Rakha EA; Claire Paish E; Powe DG; Ellis IO
    Histopathology; 2009 Mar; 54(4):419-27. PubMed ID: 19309393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
    Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
    J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
    Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
    Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do Different Stemness Markers Identify Different Pools of Cancer Stem Cells in Malignancies: A Study on ER+ and ER-Breast Cancer Cell Lines.
    Chopra S; Goel S; Thakur B; Bhatia A
    Pathol Oncol Res; 2020 Jan; 26(1):371-378. PubMed ID: 30361903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor conversion in distant breast cancer metastases.
    Hoefnagel LD; van de Vijver MJ; van Slooten HJ; Wesseling P; Wesseling J; Westenend PJ; Bart J; Seldenrijk CA; Nagtegaal ID; Oudejans J; van der Valk P; van der Groep P; de Vries EG; van der Wall E; van Diest PJ
    Breast Cancer Res; 2010; 12(5):R75. PubMed ID: 20863372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.
    Groenendijk FH; Zwart W; Floore A; Akbari S; Bernards R
    Breast Cancer Res Treat; 2013 Aug; 140(3):475-84. PubMed ID: 23912957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
    Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ
    Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target.
    Skliris GP; Leygue E; Watson PH; Murphy LC
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):1-10. PubMed ID: 18243688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1.
    Wang Y; Qu Y; Zhang XL; Xing J; Niu XL; Chen X; Li ZM
    Mol Cell Endocrinol; 2014 Feb; 382(2):791-803. PubMed ID: 24189439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
    Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
    Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between progesterone receptor membrane component 1 and estrogen receptor α promotes breast cancer cell proliferation.
    Pedroza DA; Subramani R; Tiula K; Do A; Rashiraj N; Galvez A; Chatterjee A; Bencomo A; Rivera S; Lakshmanaswamy R
    Lab Invest; 2021 Jun; 101(6):733-744. PubMed ID: 33903732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters.
    Matthews J; Wihlén B; Tujague M; Wan J; Ström A; Gustafsson JA
    Mol Endocrinol; 2006 Mar; 20(3):534-43. PubMed ID: 16293641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoxin A4 regulates expression of the estrogen receptor and inhibits 17β-estradiol induced p38 mitogen-activated protein kinase phosphorylation in human endometriotic stromal cells.
    Chen S; Wu RF; Su L; Zhou WD; Zhu MB; Chen QH
    Fertil Steril; 2014 Jul; 102(1):264-71. PubMed ID: 24835059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.